Literature DB >> 17688

Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats.

W Schmidt, E Jähnchen.   

Abstract

The elimination, distribution and anticoagulant activity of S(-)-, R(+)-, and R,S(+/-)- phenoprocoumon were determined in male Wistar-Lewis rats after intravenous injection of a single dose of 0.6 mg kg-1. From the plasma concentrations which elicited the same anticoagulant effect, S(-)-phenprocoumon was 4 to 5 times more potent than R(+)-phenprocouman. The potency of the racemate was between those of the enantiomers. The mean biologic half-life of the S(-)-enantiomer was shorter (12-5 h) than that of R(+)-phenprocoumon (17-8 h). No differences were observed in the apparent volume of distribution. However, the mean liver:plasma concentration ratio was higher for the S(-)-(6-9) than for the R(+)-enantiomer (5-2). At a total concentration of 16-8 microgram ml-1 the percentage of unbound drug in rat serum was significantly higher for the S(-)- (1-13%) than that for the R(+)-enantiomer (0.76%). Values obtained for the racemate were always between those of the enantiomers. It is concluded that stereoselective differences in the distribution between plasma and liver, and consequently in the rate of elimination are most likely due to stereoselective differences in serum protein binding. The greater anticoagulant potency of the S(-)- over the R(+)-enantiomer, cannot be explained primarily by the observed pharmacokinetic differences.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 17688     DOI: 10.1111/j.2042-7158.1977.tb11309.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  8 in total

1.  Species-dependent stereospecific serum protein binding of the oral anticoagulant drug phenprocoumon.

Authors:  W Schmidt; E Jähnchen
Journal:  Experientia       Date:  1978-10-15

Review 2.  Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.

Authors:  Mike Ufer
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Effect of serum protein binding on pharmacokinetics and anticoagulant activity of phenprocoumon in rats.

Authors:  D Trenk; E Jähnchen
Journal:  J Pharmacokinet Biopharm       Date:  1980-04

4.  Anticoagulant activity of the enantiomers of acenocoumarol.

Authors:  T Meinertz; W Kasper; C Kahl; E Jähnchen
Journal:  Br J Clin Pharmacol       Date:  1978-02       Impact factor: 4.335

Review 5.  New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

Authors:  Francesco Scaglione
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

6.  Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.

Authors:  M L Becker; W P J Franken; F Karapinar; R Verzijl-Zeegers; T Schalekamp; R T M van der Hoeven
Journal:  Eur J Clin Pharmacol       Date:  2015-09-24       Impact factor: 2.953

7.  Interaction of phenylbutazone with racemic phenprocoumon and its enantiomers in rats.

Authors:  W Schmidt; E Jähnchen
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

8.  Vitamin K 2,3-epoxide reductase: the basis for stereoselectivity of 4-hydroxycoumarin anticoagulant activity.

Authors:  H H Thijssen; L G Baars; H T Vervoort-Peters
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.